Stockrabit · Analysts
Questions across 1 call

Abdul Kader

ICICI Securities

Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited CC-Mar25.pdf · 2025-05-06
Yes. Hi. Thank you for the opportunity. So, my first question is with regards to your order book and capacity addition. So, in your opening remarks, you talked about a strong order book and, you know, you're talking about increasing your capacity also to close to 90 million. So, I mean, you know, how should we look at the utilization part considering, you know, you're talking about a significant capacity to be added in, you know, across your business segments over the next 1, 1.5 year period?
Got it, sir. Sir, my next question is pertaining to your NCE and NBE projects. So, I see in your list deck that there is one new project getting added this quarter. So, any color on, you know, by when would, you know, the revenue booking in a meaningful way happen from this particular segment? And, you know, in your DDC business and specific with your biologic NBE, NCE part of the business.